Catalyst Pharmaceuticals, Inc. has filed an amendment to its previously submitted Form 8-K, correcting a scrivener's error regarding the signature date. The original report was filed on March 18, 2026, and the amendment was submitted to the SEC on the same date. This amendment does not introduce any new information or changes to the content of the original filing, which primarily pertains to the company's ongoing legal matters. The filing indicates that the District Court for the District of New Jersey has delayed the start of the bench trial between Catalyst and Hetero USA, Inc. from March 23, 2026, to May 18, 2026. This trial concerns the validity of Catalyst's Orange Book-listed patents related to its product FIRDAPSE, which are set to expire in 2032, 2034, and 2037. The company continues to navigate its legal landscape while maintaining its operational focus. The amendment is classified as administrative in nature and is not expected to have any significant impact on the company's stock price or market perception.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.